Research
Hormonal
Abdominal obesity indices (CVAI, NC, WC, WHR, LAP, VAI) are not associated with the prevalence of diabetic retinopathy (DR) in diabetic adults, regardless of BMI adjustment.
Clinicians should not rely on abdominal obesity indices (like CVAI or Neck Circumference) to screen for diabetic retinopathy risk. Regular eye exams remain the gold standard for DR detection, as these body measurements do not correlate with retinal disease prevalence in diabetic patients.
GoodRefutesHIGH confidence
in both men and women, a one SD increase in NC, WC, WHR, LAP, VAI, and CVAI was not associated with the prevalence of DR (all P for trend > 0.05)... no significant associations of BMI, NC, WC, WHR, LAP, VAI, and CVAI with the prevalence of DR among men or women were found.
Why this rating
Large sample size and consistent findings across genders.
Source
Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference
Heng Wan et al. · Cardiovascular Diabetology · 2020
DOI 10.1186/s12933-020-01095-4
cross_sectional · n=4658Cited 306×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Higher Chinese visceral adiposity index (CVAI) is significantly associated with increased prevalence of cardiovascular disease (CVD) and diabetic kidney disease (DKD) in diabetic adults, independent of BMI.Good
- Neck circumference (NC) is uniquely associated with the prevalence of common carotid artery (CCA) plaque in diabetic adults, independent of other abdominal obesity indices.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →